Literature DB >> 34173121

The impact of transanal local excision of early rectal cancer on completion rectal resection without neoadjuvant chemoradiotherapy: a systematic review.

R Zinicola1, R Nascimbeni2, R Cirocchi3, G Gagliardi4, N Cracco5, M Giuffrida6, G Pedrazzi7, G A Binda8.   

Abstract

BACKGROUND: The impact of transanal local excision (TAE) of early rectal cancer (ERC) on subsequent completion rectal resection (CRR) for unfavorable histology or margin involvement is unclear. The aim of this study was to provide a comprehensive review of the literature on the impact of TAE on CRR in patients without neoadjuvant chemoradiotherapy (CRT).
METHODS: We performed a systematic review of the literature up to March 2020. Medline and Cochrane libraries were searched for studies reporting outcomes of CRR after TAE for ERC. We excluded patients who had neoadjuvant CRT and endoscopic local excision. Surgical, functional, pathological and oncological outcomes were assessed. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed.
RESULTS: Sixteen studies involving 353 patients were included. Pathology following TAE was as follows T0 = 2 (0.5%); T1 = 154 (44.7%); T2 = 142 (41.2%); T3 = 43 (12.5%); Tx = 3 (0.8%); T not reported = 9. Fifty-three percent were > T1. Abdominoperineal resection (APR) was performed in 80 (23.2%) patients. Postoperative major morbidity and mortality occurred in 22 (11.4%) and 3 (1.1%), patients, respectively. An incomplete mesorectal fascia resulting in defects of the mesorectum was reported in 30 (24.6%) cases. Thirteen (12%) patients developed recurrence: 8 (3.1%) local, 19 (7.3%) distant, 4 (1.5%) local and distant. The 5-year cancer-specific survival was 92%. Only 1 study assessed anal function reporting no continence disorders in 11 patients. In the meta-analysis, CRR after TAE showed an increased APR rate (OR 5.25; 95% CI 1.27-21.8; p 0.020) and incomplete mesorectum rate (OR 3.48; 95% CI 1.32-9.19; p 0.010) compared to primary total mesorectal excision (TME). Two case matched studies reported no difference in recurrence rate and disease free survival respectively.
CONCLUSIONS: The data are incomplete and of low quality. There was a tendency towards an increased risk of APR and poor specimen quality. It is necessary to improve the accuracy of preoperative staging of malignant rectal tumors in patients scheduled for TAE.

Entities:  

Keywords:  Completion proctectomy; Completion rectal resection; Early anterior resection; Early rectal cancer; Early salvage proctectomy; Surgical transanal excision; Transanal endoscopic microsurgery

Year:  2021        PMID: 34173121     DOI: 10.1007/s10151-020-02401-8

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  43 in total

1.  Methodological index for non-randomized studies (minors): development and validation of a new instrument.

Authors:  Karem Slim; Emile Nini; Damien Forestier; Fabrice Kwiatkowski; Yves Panis; Jacques Chipponi
Journal:  ANZ J Surg       Date:  2003-09       Impact factor: 1.872

2.  Does previous transanal excision for early rectal cancer impair surgical outcomes and pathologic findings of completion total mesorectal excision? Results of a systematic review of the literature.

Authors:  Y Eid; A Alves; J Lubrano; B Menahem
Journal:  J Visc Surg       Date:  2018-04-12       Impact factor: 2.043

Review 3.  Outcomes following completion and salvage surgery for early rectal cancer: A systematic review.

Authors:  Helen J S Jones; Chris Cunningham; Gary A Nicholson; Roel Hompes
Journal:  Eur J Surg Oncol       Date:  2017-11-14       Impact factor: 4.424

4.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; L Wyrwicz; E Tiret; G Brown; C Rödel; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

5.  Transanal Endoscopic Microsurgery (TEM) for Rectal Cancer: University Hospital of North Tees Experience.

Authors:  Khalid A Osman; Daniel Ryan; Sorena Afshar; Zakir K Mohamed; Dharmendra Garg; Talvinder Gill
Journal:  Indian J Surg       Date:  2014-04-29       Impact factor: 0.656

6.  Previous transanal full-thickness excision increases the morbidity of radical resection for rectal cancer.

Authors:  G Piessen; C Cabral; S Benoist; C Penna; B Nordlinger
Journal:  Colorectal Dis       Date:  2012-04       Impact factor: 3.788

7.  Immediate radical resection after local excision of rectal cancer: an oncologic compromise?

Authors:  Dieter Hahnloser; Bruce G Wolff; David W Larson; Jennifer Ping; Santhat Nivatvongs
Journal:  Dis Colon Rectum       Date:  2005-03       Impact factor: 4.585

8.  Local excision of rectal cancer followed by radical surgery because of poor prognostic features does not compromise the long term oncologic outcome.

Authors:  G Gagliardi; T R Newton; H R Bailey
Journal:  Colorectal Dis       Date:  2013-11       Impact factor: 3.788

9.  Does transanal local resection increase morbidity for subsequent total mesorectal excision for early rectal cancer?

Authors:  C Coton; J H Lefevre; C Debove; B Creavin; N Chafai; E Tiret; Y Parc
Journal:  Colorectal Dis       Date:  2018-10-30       Impact factor: 3.788

10.  Local excision followed by early radical surgery in rectal cancer: long-term outcome.

Authors:  Theodor Junginger; Ursula Goenner; Mirjam Hitzler; Tong T Trinh; Achim Heintz; Daniel Wollschläger
Journal:  World J Surg Oncol       Date:  2019-10-08       Impact factor: 2.754

View more
  2 in total

1.  Long-term results of minimally invasive transanal surgery for rectal tumors in 249 consecutive patients.

Authors:  Kotaro Maeda; Yoshikazu Koide; Hidetoshi Katsuno; Yosuke Tajima; Tsunekazu Hanai; Koji Masumori; Hiroshi Matsuoka; Miho Shiota
Journal:  Surg Today       Date:  2022-08-12       Impact factor: 2.540

2.  Prevalence of occult hepatitis B among HIV-positive individuals in Africa: A systematic review and meta-analysis.

Authors:  Violet Dismas Kajogoo; Sylivia Sarah Swai; Sanyukta Gurung
Journal:  SAGE Open Med       Date:  2022-01-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.